SOURCE: AtheroGenics, Inc.

April 17, 2008 09:18 ET

AtheroGenics to Report First Quarter 2008 Financial Results on April 24, 2008

ATLANTA, GA--(Marketwire - April 17, 2008) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it will release its first quarter 2008 financial results on Thursday, April 24, 2008 before the U.S. financial markets open.

Conference Call and Webcast Information

Company officials will discuss first quarter 2008 financial results via conference call and webcast on Thursday, April 24, 2008, at 9:00 a.m. EDT. Participants may access the live conference call by dialing 877-407-8031 (domestic) or 201-689-8031 (international). To access the webcast, please visit the AtheroGenics Investor Relations website at www.atherogenics.com. A replay of the conference call will be accessible approximately one hour after the conclusion of the call by dialing 877-660-6853 (domestic) or 201-612-7415 (international), account number 286, conference ID number 281784. A replay of the webcast will be archived on the Company's website until July 25, 2008.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). The Company's lead product candidate, AGI-1067, is a novel antioxidant and anti-inflammatory agent that is currently being evaluated in a Phase III registration study called ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study) as an oral treatment for Type 2 diabetes. In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection. For more information about AtheroGenics, please visit http://www.atherogenics.com.

Contact Information

  • CONTACTS:
    AtheroGenics, Inc.
    Donna L. Glasky
    Corporate Communications
    678-336-2517
    Email Contact

    Media Inquiries
    Jayme Maniatis / Dana Conti
    Schwartz Communications, Inc.
    781-684-0770
    Email Contact

    Investor Inquiries
    Lilian Stern
    Stern Investor Relations, Inc.
    212-362-1200
    Email Contact